SCT抗体;SCT Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P11340(SCT Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P11340(SCT Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

SCT antibodies, commonly linked to stem cell transplantation (SCT), are critical in mediating immune responses during or after transplantation. In allogeneic SCT, donor-derived immune cells may recognize recipient tissues as foreign, triggering graft-versus-host disease (GVHD), while residual host immunity can attack donor cells, causing graft rejection. Antibodies targeting human leukocyte antigens (HLA) are particularly significant, as pre-existing or post-transplant anti-HLA antibodies correlate with graft failure, delayed engraftment, or poor outcomes. These antibodies are routinely screened pre-transplant to optimize donor-recipient compatibility.

Beyond transplantation, "SCT antibodies" may also refer to antibodies against specific antigens like the secretin receptor (SCTR), implicated in autoimmune or gastrointestinal disorders. However, their primary clinical relevance remains in SCT settings. Research focuses on understanding antibody-mediated rejection mechanisms, developing desensitization protocols, and refining immunosuppressive therapies to improve transplant success. Monitoring and managing these antibodies are vital for reducing complications, enhancing engraftment, and ensuring long-term patient survival. Ongoing studies explore biomarkers and therapeutic strategies to modulate antibody responses, highlighting their dual role as both pathogenic agents and therapeutic targets in transplant immunology.